RxDoctor Payments Data

Renita Richardson, NP

Nurse Practitioner · Fayetteville, GANPI 1245792506

Payments from drug & device makers

$4,825in general payments, 2019–2025

Across 203 payments — averaging $23.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$505
  • Merck$492
  • Pfizer$353
  • Boehringer Ingelheim$328
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$308
  • E.r. Squibb & Sons, L.L.C.$303
  • plus $3K from 26 others

What the payments were for

  • Food & beverage$4,825100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,825 in reported general payments places this provider in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$73,019
Medicare patients
610
Services billed
847

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban63$69,752
JardianceEmpagliflozin12$15,491
Hydralazine Hcl62$848
Metoprolol Succinate88$819
Atorvastatin Calcium65$741
Amlodipine Besylate118$726
Isosorbide Mononitrate ErIsosorbide Mononitrate56$661
Metoprolol Tartrate74$521
Losartan Potassium75$516
Olmesartan Medoxomil19$423
Rosuvastatin Calcium27$396
Carvedilol68$313
Diltiazem 24hr Er (Cd)Diltiazem Hcl11$296
Furosemide69$260
Potassium Chloride18$244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$353$69,75263 claims
Boehringer IngelheimJardiance$328$15,49112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Fayetteville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →